Head of the Gamaleya Center Gunzburg: the study will decide on the use of a nasal vaccine 
the results of tests in the framework of clinical trials, said the director of the Gamaleya center Alexander Gintsburg, writes RIA Novosti.
According to him, there is still no definite answer whether this drug can replace the usual vaccine. He also did not specify whether the nasal vaccine will be used as an adjunct to the vaccine, for example, during revaccination. “One of the questions that will be resolved during this clinical study will be the one that you have just asked me,” the head of the center replied to journalists.
In the center of Gamalea, two nasal vaccines against COVID-19 based on the drug “Sputnik V”. The license to develop the second drug was granted by Generium. The center itself intends to produce a nasal form of “Sputnik V” in the form of a frozen solution, Gunzburg recalled. The end of preclinical trials of the drug was reported in August.
According to virologist Anatoly Altstein, the advantage of the nasal vaccine is that it can produce more class A immunoglobulins. Immunoglobulins G, which are formed in the body after intramuscular injection, are found a virus only when it enters the body.